{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:19Z","timestamp":1792783099573,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR001870"],"award-info":[{"award-number":["KL2TR001870"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR000143"],"award-info":[{"award-number":["KL2TR000143"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cannonball Kids\u2019 Cancer Foundation","award":["A129749"],"award-info":[{"award-number":["A129749"]}]},{"DOI":"10.13039\/100013195","name":"William M. Wood Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013195","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009540","name":"Frank A. Campini Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11060-018-2991-5","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T17:12:00Z","timestamp":1536685920000},"page":"629-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience"],"prefix":"10.1007","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7765-7690","authenticated-orcid":false,"given":"Cassie","family":"Kline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. John","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Duriseti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Nicolaides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Raber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalin","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Haas-Kogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"2991_CR1","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1064::AID-CNCR24>3.0.CO;2-1","volume":"86","author":"J Allen","year":"1999","unstructured":"Allen J, Siffert J, Donahue B et al (1999) A phase I\/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 86:1064\u20131069","journal-title":"Cancer"},{"key":"2991_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.pcl.2014.09.011","volume":"62","author":"M Chintagumpala","year":"2015","unstructured":"Chintagumpala M, Gajjar A (2015) Brain tumors. Pediatr Clin North Am 62:167\u2013178. \n                    https:\/\/doi.org\/10.1016\/j.pcl.2014.09.011","journal-title":"Pediatr Clin North Am"},{"key":"2991_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11864-001-0074-9","volume":"2","author":"KJ Cohen","year":"2001","unstructured":"Cohen KJ, Broniscer A, Glod J (2001) Pediatric glial tumors. Curr Treat Options Oncol 2:529\u2013536. \n                    https:\/\/doi.org\/10.1007\/s11864-001-0074-9","journal-title":"Curr Treat Options Oncol"},{"key":"2991_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2217\/cns.14.47","volume":"3","author":"EC Kaye","year":"2014","unstructured":"Kaye EC, Baker JN, Broniscer A (2014) Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis. CNS Oncol 3:421\u2013431. \n                    https:\/\/doi.org\/10.2217\/cns.14.47","journal-title":"CNS Oncol"},{"key":"2991_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/1817-1745.165656","volume":"10","author":"S Lam","year":"2015","unstructured":"Lam S, Lin Y, Auffinger B, Melkonian S (2015) Analysis of survival in pediatric high-grade brainstem gliomas: A population-based study. J Pediatr Neurosci 10:199\u2013206. \n                    https:\/\/doi.org\/10.4103\/1817-1745.165656","journal-title":"J Pediatr Neurosci"},{"key":"2991_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00001622-199405000-00004","volume":"6","author":"RJ Packer","year":"1994","unstructured":"Packer RJ (1994) Diagnosis, treatment, and outcome of primary central nervous system tumors of childhood. Curr Opin Oncol 6:240\u2013246","journal-title":"Curr Opin Oncol"},{"key":"2991_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","volume":"7","author":"D Hargrave","year":"2006","unstructured":"Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241\u2013248. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(06)70615-5","journal-title":"Lancet Oncol"},{"key":"2991_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1586\/14737140.2015.974563","volume":"15","author":"SEM van VeldhuijzenZanten","year":"2015","unstructured":"Veldhuijzen van Zanten SEM, Jansen MHA, Sanchez Aliaga E et al (2015) A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Rev Anticancer Ther 15:157\u2013164. \n                    https:\/\/doi.org\/10.1586\/14737140.2015.974563","journal-title":"Expert Rev Anticancer Ther"},{"key":"2991_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fonc.2015.00028","volume":"5","author":"S Walston","year":"2015","unstructured":"Walston S, Hamstra DA, Oh K et al (2015) A multi-institutional experience in pediatric high-grade glioma. Front Oncol 5:28. \n                    https:\/\/doi.org\/10.3389\/fonc.2015.00028","journal-title":"Front Oncol"},{"key":"2991_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1634\/theoncologist.9-2-197","volume":"9","author":"A Broniscer","year":"2004","unstructured":"Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9:197\u2013206","journal-title":"Oncologist"},{"key":"2991_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1006193306286","volume":"40","author":"SE Schild","year":"1998","unstructured":"Schild SE, Stafford SL, Brown PD et al (1998) The results of radiotherapy for brainstem tumors. J Neurooncol 40:171\u2013177","journal-title":"J Neurooncol"},{"key":"2991_CR12","doi-asserted-by":"publisher","first-page":"42837","DOI":"10.18632\/oncotarget.10034","volume":"7","author":"J Nazarian","year":"2016","unstructured":"Nazarian J, Mason GE, Ho CY et al (2016) Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. Oncotarget 7:42837\u201342842. \n                    https:\/\/doi.org\/10.18632\/oncotarget.10034","journal-title":"Oncotarget"},{"key":"2991_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11060-010-0301-y","volume":"102","author":"R Sethi","year":"2011","unstructured":"Sethi R, Allen J, Donahue B et al (2011) Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol 102:121\u2013127. \n                    https:\/\/doi.org\/10.1007\/s11060-010-0301-y","journal-title":"J Neurooncol"},{"key":"2991_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0360-3016(97)00846-8","volume":"40","author":"B Donahue","year":"1998","unstructured":"Donahue B, Allen J, Siffert J et al (1998) Patterns of recurrence in brain stem gliomas: evidence for craniospinal dissemination. Radiation Oncology Biology 40:677\u2013680","journal-title":"Radiation Oncology Biology"},{"key":"2991_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11060-011-0677-3","volume":"106","author":"JE Wolff","year":"2012","unstructured":"Wolff JE, Rytting ME, Vats TS et al (2012) Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol 106:391\u2013397. \n                    https:\/\/doi.org\/10.1007\/s11060-011-0677-3","journal-title":"J Neurooncol"},{"key":"2991_CR16","doi-asserted-by":"publisher","first-page":"e26988","DOI":"10.1002\/pbc.26988","volume":"65","author":"A Lassaletta","year":"2018","unstructured":"Lassaletta A, Strother D, Laperriere N et al (2018) Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer 65:e26988. \n                    https:\/\/doi.org\/10.1002\/pbc.26988","journal-title":"Pediatr Blood Cancer"},{"key":"2991_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11060-017-2451-7","volume":"133","author":"T Miyazaki","year":"2017","unstructured":"Miyazaki T, Ishikawa E, Matsuda M et al (2017) Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol 133:277\u2013285. \n                    https:\/\/doi.org\/10.1007\/s11060-017-2451-7","journal-title":"J Neurooncol"},{"key":"2991_CR18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/neuonc\/now132","volume":"18","author":"ST Garber","year":"2016","unstructured":"Garber ST, Hashimoto Y, Weathers S-P et al (2016) Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology 18:1357\u20131366. \n                    https:\/\/doi.org\/10.1093\/neuonc\/now132","journal-title":"Neuro-Oncology"},{"key":"2991_CR19","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","volume":"17","author":"AS Berghoff","year":"2015","unstructured":"Berghoff AS, Kiesel B, Widhalm G et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology 17:1064\u20131075. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nou307","journal-title":"Neuro-Oncology"},{"key":"2991_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-018-2886-5","volume":"54","author":"K Hwang","year":"2018","unstructured":"Hwang K, Koh EJ, Choi EJ et al (2018) PD-1\/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol 54:307\u2013311. \n                    https:\/\/doi.org\/10.1007\/s11060-018-2886-5","journal-title":"J Neurooncol"},{"key":"2991_CR21","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1002\/cncr.30724","volume":"123","author":"RG Majzner","year":"2017","unstructured":"Majzner RG, Simon JS, Grosso JF et al (2017) Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer 123:3807\u20133815. \n                    https:\/\/doi.org\/10.1002\/cncr.30724","journal-title":"Cancer"},{"key":"2991_CR22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet E, Larouche V, Campbell BB et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206\u20132211. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.66.6552","journal-title":"J Clin Oncol"},{"key":"2991_CR23","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","volume":"20","author":"DA Wainwright","year":"2014","unstructured":"Wainwright DA, Chang AL, Dey M et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 20:5290\u20135301. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0514","journal-title":"Clin Cancer Res"},{"key":"2991_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon DA, Gokhale PC, Klein SR et al (2016) Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 4:124\u2013135. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0151","journal-title":"Cancer Immunol Res"},{"key":"2991_CR25","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16:e498\u2013e509. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"key":"2991_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","volume":"86","author":"J Zeng","year":"2013","unstructured":"Zeng J, See AP, Phallen J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343\u2013349. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2012.12.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2991_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/bs.ai.2015.12.005","volume":"130","author":"MD Hellmann","year":"2016","unstructured":"Hellmann MD, Friedman CF, Wolchok JD (2016) Combinatorial cancer immunotherapies. Adv Immunol 130:251\u2013277. \n                    https:\/\/doi.org\/10.1016\/bs.ai.2015.12.005","journal-title":"Adv Immunol"},{"key":"2991_CR28","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368\u2013375. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2991_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","volume":"117","author":"JPS Knisely","year":"2012","unstructured":"Knisely JPS, Yu JB, Flanigan J et al (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227\u2013233. \n                    https:\/\/doi.org\/10.3171\/2012.5.JNS111929","journal-title":"J Neurosurg"},{"key":"2991_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11060-017-2643-1","volume":"136","author":"I Fried","year":"2018","unstructured":"Fried I, Lossos A, Ben Ami T et al (2018) Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. J Neurooncol 136:189\u2013195. \n                    https:\/\/doi.org\/10.1007\/s11060-017-2643-1","journal-title":"J Neurooncol"},{"key":"2991_CR31","doi-asserted-by":"crossref","unstructured":"Hwang EOA, Young-Poussaint T, Mitchell D et al (2018) Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): a Pediatric Brain Tumor Consortium sutdy (PBTC045). In: International Society of Pediatric Neuro-Oncology; July 1\u2013July 3, Denver, CO Abstract presented as IMMU-09","DOI":"10.1093\/neuonc\/noy059.325"},{"key":"2991_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1302369","journal-title":"N Engl J Med"},{"key":"2991_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/neuonc\/nov071","volume":"17","author":"G Vlahovic","year":"2015","unstructured":"Vlahovic G, Fecci PE, Reardon D, Sampson JH (2015) Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro-Oncol 17:1043\u20131045. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nov071","journal-title":"Neuro-Oncol"},{"key":"2991_CR34","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-16-0108","author":"H Trainer","year":"2016","unstructured":"Trainer H, Hulse P, Higham CE et al (2016) Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep. \n                    https:\/\/doi.org\/10.1530\/EDM-16-0108","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2991_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11523-016-0426-9","volume":"11","author":"JW Vandiver","year":"2016","unstructured":"Vandiver JW, Singer Z, Harshberger C (2016) Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Target Oncol 11:553\u2013556. \n                    https:\/\/doi.org\/10.1007\/s11523-016-0426-9","journal-title":"Target Oncol"},{"key":"2991_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2016.12.007","volume":"73","author":"GO Janssens","year":"2017","unstructured":"Janssens GO, Gandola L, Bolle S et al (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG\/DIPG working group. Eur J Cancer 73:38\u201347. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.12.007","journal-title":"Eur J Cancer"},{"key":"2991_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.prro.2016.11.005","volume":"7","author":"C Freese","year":"2017","unstructured":"Freese C, Takiar V, Fouladi M et al (2017) Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Pract Radiat Oncol 7:86\u201392. \n                    https:\/\/doi.org\/10.1016\/j.prro.2016.11.005","journal-title":"Pract Radiat Oncol"},{"key":"2991_CR38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11060-014-1428-z","volume":"118","author":"M Massimino","year":"2014","unstructured":"Massimino M, Biassoni V, Miceli R et al (2014) Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol 118:305\u2013312. \n                    https:\/\/doi.org\/10.1007\/s11060-014-1428-z","journal-title":"J Neurooncol"},{"key":"2991_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/COC.0b013e318201a2b7","volume":"35","author":"HP Fontanilla","year":"2012","unstructured":"Fontanilla HP, Pinnix CC, Ketonen LM et al (2012) Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol 35:51\u201357. \n                    https:\/\/doi.org\/10.1097\/COC.0b013e318201a2b7","journal-title":"Am J Clin Oncol"},{"key":"2991_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","volume":"130","author":"D Castel","year":"2015","unstructured":"Castel D, Philippe C, Calmon R et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130:815\u2013827. \n                    https:\/\/doi.org\/10.1007\/s00401-015-1478-0","journal-title":"Acta Neuropathol"},{"key":"2991_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","volume":"124","author":"D-A Khuong-Quang","year":"2012","unstructured":"Khuong-Quang D-A, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439\u2013447. \n                    https:\/\/doi.org\/10.1007\/s00401-012-0998-0","journal-title":"Acta Neuropathol"},{"key":"2991_CR42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0360-3016(98)00501-X","volume":"43","author":"LR Mandell","year":"1999","unstructured":"Mandell LR, Kadota R, Freeman C et al (1999) There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Radiat Oncol Biol 43:959\u2013964","journal-title":"Radiat Oncol Biol"},{"key":"2991_CR43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0360-3016(93)90228-N","volume":"27","author":"CR Freeman","year":"1993","unstructured":"Freeman CR, Krischer JP, Sanford RA et al (1993) Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Radiat Oncol Biol 27:197\u2013206","journal-title":"Radiat Oncol Biol"},{"key":"2991_CR44","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3174\/ajnr.A5159","volume":"38","author":"P Svolos","year":"2017","unstructured":"Svolos P, Reddick WE, Edwards A et al (2017) Measurable supratentorial white matter volume changes in patients with diffuse intrinsic pontine glioma treated with an anti-vascular endothelial growth factor agent, steroids, and radiation. AJNR Am J Neuroradiol 38:1235\u20131241. \n                    https:\/\/doi.org\/10.3174\/ajnr.A5159","journal-title":"AJNR Am J Neuroradiol"},{"key":"2991_CR45","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1200\/JCO.2009.22.4998","volume":"27","author":"MJ van den Bent","year":"2009","unstructured":"van den Bent MJ, Vogelbaum MA, Wen PY et al (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald\u2019s Criteria. J Clin Oncol 27:2905\u20132908. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.22.4998","journal-title":"J Clin Oncol"},{"key":"2991_CR46","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bjc.2015.238","volume":"113","author":"ET Wong","year":"2015","unstructured":"Wong ET, Lok E, Gautam S, Swanson KD (2015) Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 113:232\u2013241. \n                    https:\/\/doi.org\/10.1038\/bjc.2015.238","journal-title":"Br J Cancer"},{"key":"2991_CR47","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534\u2013e542. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00088-1","journal-title":"Lancet Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2991-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2991-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2991-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T03:32:12Z","timestamp":1589686332000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2991-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2991-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"14 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript have no conflicts of interest and no financial or other interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}